Ute Schellenberger
17 Papers
76 Citations
Ute Schellenberger is an academic researcher. The author has contributed to research in topics: T cell & Antibody. The author has an hindex of 5, co-authored 17 publications.
Chat about Author
Papers
Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies.
Starlynn Clarke,Biao Ma,Nathan D. Trinklein,Ute Schellenberger,Michael J. Osborn,Laure-Hélène Ouisse,Andrew Boudreau,Laura Davison,Katherine E. Harris,Harshad Ugamraj,Aarti Balasubramani,Kevin Dang,Brett Jorgensen,Heather Ogana,Duy Pham,Payal Pratap,Preethi Sankaran,Ignacio Anegon,W.C. van Schooten,Marianne Brüggemann,Roland Buelow,S. Force Aldred +21 more
TL;DR: This work presents an innovative platform for the rapid development of diverse sets of human HCAbs that have been selected in vivo and combines antibody repertoire analysis with immunization of transgenic rats, called UniRats, that produce chimeric HCABS with fully human VH domains in response to an antigen challenge.
38
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
Kevin Dang,Giulia Castello,Starlynn Clarke,Yuping Li,Aarti Balasubramani,Andrew Boudreau,Laura Davison,Katherine E. Harris,Duy Pham,Preethi Sankaran,Harshad Ugamraj,Rong Deng,Serena S. Kwek,Alec Starzinski,Suhasini Iyer,Wim Van Schooten,Ute Schellenberger,Wenchao Sun,Nathan D. Trinklein,Roland Buelow,Ben Buelow,Lawrence Fong,Pranjali Dalvi +22 more
TL;DR: In this paper, an anti-CD3xPSMA TCE was developed for metastatic castration-resistant prostate cancer (mCRPC) using genetically engineered transgenic rats (UniRat and OmniFlic) together with an NGS-based antibody discovery pipeline.
37
Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific Antibodies.
Katherine E. Harris,Shelley Force Aldred,Laura Davison,Heather Ogana,Andrew Boudreau,Marianne Brüggemann,Michael J. Osborn,Biao Ma,Benjamin Buelow,Starlynn Clarke,Kevin Dang,Suhasini Iyer,Brett Jorgensen,Duy Pham,Payal Pratap,Udaya Rangaswamy,Ute Schellenberger,Wim Van Schooten,Harshad Ugamraj,Omid Vafa,Roland Buelow,Nathan D. Trinklein +21 more
TL;DR: The results demonstrate that OmniFlic animals produce an abundance of antigen-specific antibodies with heavy chain clonotype diversity that is similar to what has been described with unrestricted light chain use in mammals and shows that sequence-based discovery is a highly effective and efficient way to identify a large number of diverse monoclonal antibodies to a protein target of interest.
A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells.
Katherine E. Harris,Kyle J. Lorentsen,Harbani Kaur Malik-Chaudhry,Kaitlyn Loughlin,Harish Medlari Basappa,Sharon Hartstein,Ghenima Ahmil,Nicole S. Allen,Brian Avanzino,Aarti Balasubramani,Andrew Boudreau,Karen Chang,Maria-Cristina Cuturi,Laura Davison,Dennis M. Ho,Suhasini Iyer,Udaya Rangaswamy,Preethi Sankaran,Ute Schellenberger,Roland Buelow,Nathan D. Trinklein +20 more
TL;DR: In this paper, a bispecific heavy-chain only antibody was proposed to circumvent the preferential binding of IL-2 to cells that express the high affinity, trimeric receptor, IL 2Rαβγ such as endothelial cells and T-regulatory cells, respectively.
Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma.
Ben Buelow,Priya Choudry,Starlynn Clarke,Kevin Dang,Laura Davison,Shelley Force Aldred,Katherine E. Harris,Payal Pratap,Duy Pham,Udaya Rangaswamy,Ute Schellenberger,Nina Shah,Nathan D. Trinklein,Harshad Ugamraj,Arun P. Wiita,Wim Van Schooten +15 more
TL;DR: T-cell redirecting therapies such as CAR-T cells and T-cell engaging bispecific antibodies (T-BsAb) targeting B Cell Maturation Antigen (BCMA) have been highly efficacious against oncological indications.
19